Circulating miRNAs in progressive supranuclear palsy: Recent evidence and future challenges

Ida Manna; Selene De Benedittis; Andrea Quattrone

doi:10.1016/j.parkreldis.2022.06.011

Circulating miRNAs in progressive supranuclear palsy: Recent evidence and future challenges

Parkinsonism Relat Disord. 2022 Aug:101:18-19. doi: 10.1016/j.parkreldis.2022.06.011. Epub 2022 Jun 20.

Authors

Ida Manna¹, Selene De Benedittis², Andrea Quattrone²

Affiliations

¹ Institute of Molecular Bioimaging and Physiology (IBFM), National Research Council (CNR), Section of Germaneto, 88100, Catanzaro, Italy. Electronic address: ida.manna@cnr.it.
² Institute of Neurology, Department of Medical and Surgical Sciences, University "Magna Graecia," Germaneto, 88100, Catanzaro, Italy.

PMID: 35753145
DOI: 10.1016/j.parkreldis.2022.06.011

Abstract

Numerous studies have highlighted the importance of microRNA (miRNAs) in neurodegenerative diseases. However, the miRNA profiles in progressive supranuclear palsy (PSP) patients have been rarely reported. Recent evidence suggested a possible role of some dysregulated miRNAs in the cerebrospinal fluid (CSF) of PSP patients in the pathogenesis of the disease.

Publication types

Letter

MeSH terms

Circulating MicroRNA* / genetics
Humans
Neurodegenerative Diseases*
Supranuclear Palsy, Progressive* / pathology

Substances

Circulating MicroRNA